Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1No longer available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Newly Diagnosed Glioblastoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced or Metastatic Solid Tumors 1Glioma 1Carcinoma, Merkel Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × efineptakin alfa × Clear all
NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

NeoImmuneTech

Phase 1/2 Terminated
31 enrolled 12 charts
Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT04289155 2022-03-17

Individual Patient Compassionate Use of GX-I7

Genexine, Inc.

No longer available
CNSDermatologic

Glioblastoma, Glioma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡